Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicinDrug: dexamethasoneDrug: doxorubicinDrug: leucovorinDrug: mercaptopurineDrug: methotrexateDrug: mitoxantroneDrug: AsparaginaseDrug: prednisoneDrug: thioguanineDrug: vincristineRadiation: radiation therapyDrug: allopurinolDrug: bactrim
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 79
- Registration Number
- NCT00109837
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Minor and James Medical, PLLC, Seattle, Washington, United States
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT00110006
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
- Conditions
- CancerLeukemiaLymphoma
- Interventions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 47
- Registration Number
- NCT00109031
S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 112
- Registration Number
- NCT00107276
- Locations
- 🇺🇸
Big Sky Oncology, Great Falls, Montana, United States
🇺🇸Great Falls Clinic - Main Facility, Great Falls, Montana, United States
🇺🇸Kaiser Permanente Medical Center - Redwood City, Redwood City, California, United States
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: prednisoneDrug: vincristine sulfateRadiation: tositumomab and iodine I 131 tositumomab
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 86
- Registration Number
- NCT00107380
- Locations
- 🇺🇸
CCOP - Montana Cancer Consortium, Billings, Montana, United States
🇺🇸Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States
🇺🇸Northern Rockies Radiation Oncology Center, Billings, Montana, United States
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
- Conditions
- Ann Arbor Stage II Childhood Hodgkin LymphomaAnn Arbor Stage I Childhood Hodgkin LymphomaChildhood Nodular Lymphocyte Predominant B-Cell Lymphoma
- Interventions
- Procedure: Conventional SurgeryDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: PrednisoneRadiation: Radiation TherapyDrug: Vincristine Sulfate
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 188
- Registration Number
- NCT00107198
- Locations
- 🇵🇷
San Jorge Children's Hospital, San Juan, Puerto Rico
🇺🇸Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States
🇺🇸Tulane University School of Medicine, New Orleans, Louisiana, United States
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
- Conditions
- VasculitisMicroscopic PolyangiitisWegener's Granulomatosis
- Interventions
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2017-04-21
- Target Recruit Count
- 197
- Registration Number
- NCT00104299
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
- Conditions
- Wegener's GranulomatosisVasculitis
- Interventions
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 84
- Registration Number
- NCT00103792
- Locations
- 🇳🇱
University Medical Centre Groningen, Groningen, Netherlands
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaChildhood B Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 5377
- Registration Number
- NCT00103285
- Locations
- 🇺🇸
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
🇺🇸Driscoll Children's Hospital, Corpus Christi, Texas, United States
🇨🇦Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke, Quebec, Canada
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: CyclophosphamideDrug: DoxorubicinDrug: VincristineDrug: PrednisoneDrug: DexamethasoneBiological: Autologous Tumor Cell-Based VaccineDrug: IL-2
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 43
- Registration Number
- NCT00101101
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.